Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Luijf, YM; Mader, JK; Doll, W; Pieber, T; Farret, A; Place, J; Renard, E; Bruttomesso, D; Filippi, A; Avogaro, A; Arnolds, S; Benesch, C; Heinemann, L; DeVries, JH; AP@home consortium.
Accuracy and reliability of continuous glucose monitoring systems: a head-to-head comparison.
Diabetes Technol Ther. 2013; 15(8):722-727
Doi: 10.1089/dia.2013.0049
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Doll Werner
- Mader Julia
- Pieber Thomas
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- This study assessed the accuracy and reliability of three continuous glucose monitoring (CGM) systems. We studied the Animas® (West Chester, PA) Vibe™ with Dexcom® (San Diego, CA) G4™ version A sensor (G4A), the Abbott Diabetes Care (Alameda, CA) Freestyle® Navigator I (NAV), and the Medtronic (Northridge, CA) Paradigm® with Enlite™ sensor (ENL) in 20 patients with type 1 diabetes mellitus. All systems were investigated both in a clinical research center (CRC) and at home. In the CRC, patients received a meal with a delayed and increased insulin dose to induce a postprandial glucose peak and nadir. Hereafter, randomization determined which two of the three systems would be worn at home until the end of functioning, attempting use beyond manufacturer-specified lifetime. Patients performed at least five reference finger sticks per day. An analysis of variance was performed on all data points ≥15 min apart. Overall average mean absolute relative difference (MARD) (SD) measured at the CRC was 16.5% (14.3%) for NAV and 16.4% (15.6%) for ENL, outperforming G4A at 20.5% (18.2%) (P<0.001). Overall MARD when assessed at home was 14.5% (16.7%) for NAV and 16.5 (18.8%) for G4A, outperforming ENL at 18.9% (23.6%) (P=0.006). Median time until end of functioning was similar: 10.0 (1.0) days for G4A, 8.0 (3.5) days for NAV, and 8.0 (1.5) days for ENL (P=0.119). In the CRC, G4A was less accurate than NAV and ENL sensors, which seemed comparable. However, at home, ENL was less accurate than NAV and G4A. Moreover, CGM systems often show sufficient accuracy to be used beyond manufacturer-specified lifetime.
- Find related publications in this database (using NLM MeSH Indexing)
- Abdomen -
- Activities of Daily Living -
- Blood Glucose - analysis
- Blood Glucose Self-Monitoring -
- Diabetes Mellitus, Type 1 - blood
- Diabetes Mellitus, Type 1 - drug therapy
- Diabetes Mellitus, Type 1 - metabolism
- Diabetes Mellitus, Type 1 -
- Extracellular Fluid - drug effects
- Extracellular Fluid - metabolism
- Glucose - metabolism
- Humans -
- Hyperglycemia - diagnosis
- Hyperglycemia - prevention & control
- Hypoglycemia - chemically induced
- Hypoglycemia - diagnosis
- Hypoglycemia - prevention & control
- Hypoglycemic Agents - adverse effects
- Hypoglycemic Agents - therapeutic use
- Insulin - adverse effects
- Insulin - therapeutic use
- Kaplan-Meier Estimate -
- Materials Testing -
- Monitoring, Ambulatory - instrumentation
- Reproducibility of Results -
- Subcutaneous Tissue - drug effects
- Subcutaneous Tissue - metabolism